Background: The KIF6 rs20455 polymorphism has been verified as an important genetic factor of coronary heart disease (CHD), but with controversial results. The aim of this study was to explore the association between KIF6 rs20455 polymorphism and susceptibility to CHD.
Methods: All eligible studies were identified by searching Medline (mainly PubMed), EMBASE, the Web of Science, Cochrane Collaboration Database, Chinese National Knowledge Infrastructure, Wanfang Database and China Biological Medicine up to October 5, 2016.Odds ratios (ORs) with 95% confidence interval (CI) were used to explore the association between KIF6 rs20455 polymorphism and CHD risk. Begg's and Egger's tests were used to examine the publication bias. Subgroup analysis and sensitivity analysis were performed to test the reliability and stability of the results. All the analyses were carried out by Stata 12.0 software.
Results: A total of 28 publications including 50 individual studies were analyzed in this present work. There are no significant association found between KIF6 rs20455 polymorphism and CHD risk (Homozygote model: OR = 1.007, 95% CI =0.952-1.066, P = 0.801; Heterozygote model: OR = 1.009, 95% CI = 0.968-1.052, P = 0.636; Dominant model: OR = 1.007, 95% CI = 0.966-1.048, P = 0.753; Recessive model: OR = 0.989, 95% CI = 0.943-1.037, P = 0.655; Allele comparison model: OR = 1.00, 95% CI = 0.971-1.030, P = 0.988). Furthermore, subgroup analyses were performed by ethnicity, source of control.
Conclusions: Our result suggests that KIF6 rs20455 polymorphism may not be associated with CHD susceptibility. However, additional very well-designed large-scale studies are warranted to confirm our results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755295 | PMC |
| http://dx.doi.org/10.1186/s12944-017-0651-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicted deleterious variants in ABCA1, LPL, LPA and KIF6 are associated with statin response and adverse events in patients with familial hypercholesterolemia and disturb protein structure and stability.
Pharmacogenet Genomics
June 2024
Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Objectives: This study explored the association of deleterious variants in pharmacodynamics (PD) genes with statin response and adverse effects in patients with familial hypercholesterolemia (FH) and analyzed their potential effects on protein structure and stability.
Methods: Clinical and laboratory data were obtained from 144 adult FH patients treated with statins. A panel of 32 PD genes was analyzed by exon-targeted gene sequencing.
Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka.
Pharmacogenomics
October 2023
Department of Anatomy, Genetics & Biomedical Informatics, Faculty of Medicine, University of Colombo, Colombo 8, Sri Lanka.
Article Synopsis
- The study examined the genetic variations influencing statin effectiveness among a group of 426 Sri Lankans.
- The analysis revealed that certain variants, specifically rs4149056 and rs20455, had significantly higher frequencies in Sri Lankans compared to other populations.
- The findings suggest that the presence of these variants could contribute to variable responses to statin therapy and increased risk of side effects in this population.
MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy.
BMC Med Genomics
March 2021
Shanghai Biotecan Pharmaceuticals Co., Ltd, Shanghai Zhangjiang Institute of Medical Innovation, 180 Zhangheng Road, Shanghai, 200120, China.
Background: To determine the clinical value of multigene polymorphisms, LDL-C and sdLDL-C on T2DM therapy.
Methods: In total, 352 T2DM patients before and after treatment and 48 healthy individuals were enrolled in this study. LDL-C and sdLDL-C were detected in 352 T2DM patients and 48 healthy individuals by Quantimetrix Lipoprint System.
Are and polymorphisms associated with power and endurance athletes?
Eur J Sport Sci
September 2021
Faculty of Physical Education, Gdansk University of Physical Education and Sport, Gdansk, Poland.
Genetic polymorphisms within physiologically relevant and genes were examined in the context of athletic performance. KIF6 and ApoE are involved in cardiovascular health, modulation of lipid level and neurotransmission amongst others. The aim of this study was to examine whether three polymorphisms, rs20455T > C, rs429358T > C and rs7412 C > T, were associated with athletic status of an athlete defined as performance type (endurance or power).
View Article and Find Full Text PDFKIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.
PLoS One
April 2019
Clinical laboratory, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Introduction: The therapeutic response to statins has a high interindividual variability with respect to reductions in plasma LDL-cholesterol (c-LDL) and increases in HDL cholesterol (c-HDL). Many studies suggest that there is a relationship between the rs20455 KIF6 gene variant (c.2155T> C, Trp719Arg) and a lower risk of cardiovascular disease in patients being treated with statins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!